Efficacy and safety of rh-endostatin combined with docetaxel for progressive disease after first-line treatment in patients with advanced non-small cell lung cancer
10.3760/cma.j.issn.1008-6315.2015.12.019
- VernacularTitle:多西他赛联合重组人血管内皮抑素对初治后进展非小细胞肺癌患者的临床评价
- Author:
Xiaoling DENG
;
Shanqian HUANG
;
Fan YANG
- Publication Type:Journal Article
- Keywords:
Non-small-cell lung carcinoma;
Docetaxel;
rh-endostatin;
Chemotherapy
- From:
Clinical Medicine of China
2015;31(12):1117-1120
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the efficacy and safety of combination of rh-endostatin (Endostar) with docetaxel treatment on patients of non-small cell lung cancer (NSCLC) who presented progressive disease (PD) after first-1ine chemotherapy.Methods From Janury 2010 to March 2013,76 patients with stage Ⅲ B/ Ⅳof NSCLC experienced previous chemotherapy of one-regimen were screened for this trial.Given docetaxel combined with recombinant human endostatin (combined group, 38 cases) and docetaxel (chemotherapy group, 38 cases) to continue treatment.The response, time to progression(TTP) and adverse effects were observed in both groups.Results The objective response rate (ORR) and clinical benefit rate (CBR) were 0 and 63.2％ (24/38) in the combined group, along with 0 and 52.6％ (20/38) in the single docetaxel group, with a nonsignificant difference between the two groups (P =0.712).The median TTPs in the combined and single docetaxel groups were (2.6±0.4) months and (2.0±0.8) months respectively (P =0.083).The median TTPs of the patients with SD after therapeutic cycles in the combined and single docetaxel groups were (6.2±0.4) months and (3.2 ± 0.8) months respectively (P =0.038).The differences between two groups were nonsignificant in adverse, serious adverse and cardiovascular adverse effects(P＞0.05).Conclusion Endostar may prolong TTP in patients with advanced NSCLC benefited from docetaxel treatment without increased toxicities.
